What is the latest NH stock price?
The latest stored price for NH is Rs 1,928.50 as of 2026-09-18.
gimli
NH stock AI analysis
NH Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
NARAYANA HRUDAYALAYA LTD. is a mid-cap stock in Healthcare. This Gimli page shows the latest available NH price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹1,928.50
1W return
+0.98%
1M return
+6.96%
3M return
+3.18%
6M return
+14.11%
1Y return
+7.87%
Market cap
₹39,167.80 cr
PE
47.99
PB
8.63
ROE
+19.98%
ROCE
+15.60%
RSI
54.97
Turnover
₹52.41 cr
Why it can matter in screens
- Momentum: NH is above 50DMA, above 200DMA; RSI is 54.97.
- Returns: 1D +3.21%, 1W +0.98%, 1M +6.96%, 3M +3.18%, 1Y +7.87%.
- Trend levels: 52W high ₹2,092.90, 52W low ₹1,781.00, off high -7.86%.
- Liquidity: latest turnover is ₹52.41 cr; volume vs 20D is +1.10%.
- Valuation/profitability: PE 47.99, PB 8.63, ROE +19.98%, ROCE +15.60%.
- Growth: 3Y sales CAGR +20.69%, 3Y profit CAGR +9.94%.
Quick Answers
Is NH above its 50DMA and 200DMA?
NH is above 50DMA, above 200DMA. The latest 50DMA is 1,922.79 and the latest 200DMA is 1,858.22.
What are NH PE, ROE and ROCE?
NH has PE 47.99, ROE +19.98%, and ROCE +15.60% in Gimli's latest available snapshot.
How has NH performed recently?
NH has returned +6.96% over 1 month, +3.18% over 3 months, and +7.87% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 2,683.63 cr | 503.27 cr | 207.18 cr | 10.20 |
| 2026-03-31 | 2,593.81 cr | 537.20 cr | 223.88 cr | 11.02 |
| 2025-12-31 | 2,151.17 cr | 337.64 cr | 126.70 cr | 6.24 |
| 2025-09-30 | 1,643.79 cr | 425.22 cr | 258.37 cr | 12.72 |
| 2025-06-30 | 1,507.27 cr | 360.30 cr | 196.65 cr | 9.68 |
| 2025-03-31 | 1,475.44 cr | 376.20 cr | 197.21 cr | 9.71 |
| 2024-12-31 | 1,334.59 cr | 325.71 cr | 192.94 cr | 9.50 |
| 2024-09-30 | 1,400.01 cr | 332.03 cr | n/a | 9.78 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 7,896.03 cr | 1,662.01 cr | 805.60 cr | 39.67 |
| 2025-03-31 | 5,482.98 cr | 1,361.62 cr | 790.15 cr | 38.90 |
| 2024-03-31 | 4,875.66 cr | 1,223.01 cr | 789.26 cr | 38.86 |
| 2023-03-31 | 4,491.06 cr | 1,030.69 cr | 606.25 cr | 29.85 |
| 2022-03-31 | 2,518.37 cr | 678.83 cr | 133.60 cr | nan |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 12,474.40 cr | 770.07 cr | 5,857.49 cr | 4,539.52 cr |
| 2025-03-31 | 7,265.03 cr | 457.19 cr | 2,428.37 cr | 3,628.24 cr |
| 2024-03-31 | 5,624.58 cr | 263.83 cr | 1,626.69 cr | 2,885.09 cr |
| 2023-03-31 | 4,162.09 cr | 154.76 cr | 884.17 cr | 2,132.43 cr |
| 2022-03-31 | 3,130.53 cr | 157.50 cr | 723.42 cr | 1,489.37 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 1,621.19 cr | 746.01 cr | n/a |
| 2025-03-31 | 985.78 cr | -96.18 cr | n/a |
| 2024-03-31 | 1,066.60 cr | 95.99 cr | n/a |
| 2023-03-31 | 1,084.56 cr | 562.52 cr | n/a |
| 2022-03-31 | 485.02 cr | 234.33 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +63.27% | +9.40% | +9.06% | +7.34% | +17.65% | +0.00% |
| 2026-03-31 | +63.27% | +9.98% | +9.15% | +7.24% | +16.98% | +0.00% |
| 2025-12-31 | +63.27% | +11.10% | +7.91% | +6.22% | +17.10% | +0.00% |
| 2025-09-30 | +63.85% | +10.49% | +7.76% | +5.29% | +17.29% | +0.00% |
| 2025-06-30 | +63.85% | +10.46% | +8.09% | +5.54% | +16.98% | +0.00% |
| 2025-03-31 | +63.85% | +9.66% | +8.52% | +5.71% | +17.35% | +0.00% |
| 2024-12-31 | +63.85% | +9.44% | +8.69% | +5.54% | +17.40% | +0.00% |
| 2024-09-30 | +63.85% | +9.68% | +7.90% | +4.47% | +17.95% | +0.00% |
| 2024-06-30 | +63.85% | +10.01% | +8.23% | +5.99% | +17.29% | +0.00% |
| 2024-03-31 | +63.85% | +10.91% | +9.51% | +7.18% | +15.11% | +0.00% |
| 2023-12-31 | +63.85% | +11.51% | +10.23% | +7.89% | +13.79% | +0.00% |
| 2023-09-30 | +63.85% | +11.60% | +10.89% | +8.20% | +13.05% | +0.00% |
| 2023-06-30 | +63.85% | +11.11% | +11.95% | +9.08% | +12.46% | +0.00% |
| 2023-03-31 | +63.85% | +10.36% | +14.14% | +10.87% | +11.01% | +0.00% |
| 2022-12-31 | +63.85% | +10.23% | +14.58% | +11.75% | +10.70% | +0.00% |
| 2022-09-30 | +63.85% | +9.55% | +16.62% | +13.20% | +9.29% | +0.00% |
| 2022-06-30 | +63.85% | +0.00% | +27.88% | n/a | n/a | +0.00% |
| 2022-03-31 | +63.85% | +0.00% | +28.98% | n/a | n/a | +0.00% |
| 2021-12-31 | +63.85% | +0.00% | +29.76% | n/a | n/a | +0.00% |
| 2021-09-30 | +63.85% | +0.00% | +30.37% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 440,829.82 cr | 36.388220 | +15.50% | +11.45% |
| DIVISLAB | DIVI S LABORATORIES LTD | 248,876.81 cr | 85.407280 | +18.37% | +53.39% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 163,807.57 cr | 75.106636 | +17.33% | +35.67% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,608.22 cr | 65.670049 | +21.03% | +13.94% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 116,723.14 cr | 26.011308 | +16.04% | +10.70% |
| CIPLA | CIPLA LTD | 112,647.78 cr | 33.401961 | +10.25% | -11.64% |
| LAURUSLABS | LAURUS LABS LIMITED | 105,487.98 cr | 96.587446 | +21.77% | +111.64% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 102,122.47 cr | 70.799892 | +14.33% | -10.58% |
Try these prompts
- Analyze NARAYANA HRUDAYALAYA. with valuation, momentum and industry peers
- Compare NH with other Healthcare stocks
- Show mid-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View mid-cap stocks
- Find stocks above 50DMA
- Compare NH with other Healthcare stocks
Data snapshot: 2026-09-18. Not investment advice.